Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;44(1):1-16.
doi: 10.1007/s10928-016-9500-2. Epub 2017 Jan 3.

Impact of saturable distribution in compartmental PK models: dynamics and practical use

Affiliations

Impact of saturable distribution in compartmental PK models: dynamics and practical use

Lambertus A Peletier et al. J Pharmacokinet Pharmacodyn. 2017 Feb.

Abstract

We explore the impact of saturable distribution over the central and the peripheral compartment in pharmacokinetic models, whilst assuming that back flow into the central compartiment is linear. Using simulations and analytical methods we demonstrate characteristic tell-tale differences in plasma concentration profiles of saturable versus linear distribution models, which can serve as a guide to their practical applicability. For two extreme cases, relating to (i) the size of the peripheral compartment with respect to the central compartment and (ii) the magnitude of the back flow as related to direct elimination from the central compartment, we derive explicit approximations which make it possible to give quantitative estimates of parameters. In three appendices we give detailed explanations of how these estimates are derived. They demonstrate how singular perturbation methods can be successfully employed to gain insight in the dynamics of multi-compartment pharmacokinetic models. These appendices are also intended to serve as an introductory tutorial to these ideas.

Keywords: Distribution; Pharmacokinetics; Saturation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Individual plasma concentration versus time profiles for six subjects receiving a once-daily oral 1500 mg over a period of 3 weeks. The cyan dots show the observed plasma concentrations, the black curve shows the individual fit and the grey curve the population fit of the 2-receptor model, while the magenta curves show the individual fits of the 1-receptor model
Fig. 2
Fig. 2
Linear model (2) graphs of A2(t) for increasing infusion rates q = 1, 2, 3, 4, 5 mg h-1 when ka=10, k20=10-2, kp=10-4 h-1 and H=100
Fig. 3
Fig. 3
Nonlinear model (3) graphs of A2 versus time for the parameter values ka=10, k20=10-2, kp=10-4 h-1, Bmax=3×104 mg, KM=102 mg
Fig. 4
Fig. 4
Nonlinear model (3) graphs of A2 versus time for D0=10,20,,70 for the parameter values ka=5, k20=0.2 h-1, kp=1 h-1, Bmax=100 mg, KM=10 mg
Fig. 5
Fig. 5
Variation of the plateau value A¯2(q) (left) and the normalised plateau value A¯2(q)/q (right) for the nonlinear model as they vary with q, when the data are kp=10-4 h-1, k20=10-2 h-1, the capacity takes the values: Bmax=104 (blue) 3×104 (red) and 6×104 (green) mg, and KM=100 mg
Fig. 6
Fig. 6
Terminal slopes: λz(1)(q,Bmax) (left) in the first phase and λz(2)(q,Bmax) (right) in the second phase versus the infusion rate q for the nonlinear model for two values of the capacity: Bmax=104 (red) and Bmax=3×104 mg (blue) and the rate constants ka=10, k20=10-2, kp=10-4 h-1, and KM=102 mg
Fig. 7
Fig. 7
Nonlinear model with leakage from the peripheral compartment (3) & (30). Graphs of A2 versus time for q=5 and α=0,0.5,1,2,4 for the parameter values ka=10 h-1, k20=0.01 h-1, kp=10-4 h-1, Bmax=3×104 mg, KM=102 mg

References

    1. Wagner JG, Szpunar GJ, Ferry JJ. Michaelis–Menten elimination kinetics: areas under curves, steady-state concentrations, and clearances for compartment models with different types of input. Biopharm Drug Dispos. 1985;6(2):177–200. doi: 10.1002/bdd.2510060209. - DOI - PubMed
    1. Wu X, Li J, Nekka F. Closed form solutions and dominant elimination pathways of simultaneous first-order and Michaelis–Menten kinetics. J Pharmacokinet Pharmacodyn. 2015;42:151–161. doi: 10.1007/s10928-015-9407-3. - DOI - PubMed
    1. Brocks DR, Mehvar R. Rate and extent of drug accumulation after multiple dosing revisited. Clin Pharmacokinet. 2010;49(7):421–438. doi: 10.2165/11531190-000000000-00000. - DOI - PubMed
    1. Scheerens C, Heinig R, Mueck W. Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms. Biopharm Drug Dispos. 2015;36:93–103. doi: 10.1002/bdd.1923. - DOI - PMC - PubMed
    1. Snoeck E, Jacqmin Ph, van Peer A, Danhof M. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. J Pharmacokinet Biopharm. 1999;27(3):257–281. doi: 10.1023/A:1020943029130. - DOI - PubMed

Substances

LinkOut - more resources